NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CITANEST FORTE (epinephrine bitartrate; prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CITANEST FORTE is a fixed-dose combination injectable local anesthetic containing prilocaine hydrochloride and epinephrine bitartrate. Prilocaine stabilizes neuronal membranes to block nerve impulses, while epinephrine provides vasoconstriction to extend anesthetic duration and reduce systemic absorption. It is indicated for infiltration, nerve block, and topical anesthesia in surgical and dental procedures.
LOE Approaching
As an approaching LOE product with low competitive pressure (30%), career roles are stabilization-focused rather than growth-oriented; expect modest team sizes concentrated in legacy business management.
Mechanism of Action
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CITANEST FORTE offers limited career growth and advancement opportunities due to its approaching loss of exclusivity and mature market status. Professionals pursuing roles on this product should expect responsibilities focused on market defense, volume management, and operational efficiency rather than innovation or strategic expansion.
Brand Manager
Worked on CITANEST FORTE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.